Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

NCT04252612 | Withdrawn Early Phase 1 DMC FDA Drug

• 1 other identifier: MCC-19708
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical resection specimens will then be analyzed for biological alterations.

Conditions

Cutaneous Squamous Cell Carcinoma

Outcome Measures

Primary Outcomes (1)

• Participant Compliance

  Patients who complete at least 75% of the injections and have not missed 2 consecutive days of treatment will be considered compliant.

  at 14 days from on study date

Secondary Outcomes (1)

• Number of Adverse Events

  at 44 days from on study date

Study Arms (3)

Cohort 1: Pramlintide 60 mcg twice daily

EXPERIMENTAL

Participants will self inject Pramlintide 60 mcg twice daily for two weeks prior to surgical resection of tumor.

Drug: Pramlintide

Cohort 2: Pramlintide 60 mcg three times daily

EXPERIMENTAL

Participants will self inject Parmlintide 60 mcg three times daily for two weeks prior to surgical resection of tumor.

Drug: Pramlintide

Cohort 3: Pramlintide 120 mcg three times daily

EXPERIMENTAL

Participants will self inject Parmlintide 120 mcg three times daily for two weeks prior to surgical resection of tumor.

Drug: Pramlintide

Interventions

Pramlintide DRUG

SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.

Also known as: Symlin, SymlinPen

Cohort 1: Pramlintide 60 mcg twice daily; Cohort 2: Pramlintide 60 mcg three times daily; Cohort 3: Pramlintide 120 mcg three times daily

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically proven cutaneous squamous cell carcinoma. Mixed histologies (basaloid, spindle, sarcomatoid, etc.) are allowed if the pathology review favors squamous cell carcinoma as the majority component. Cancers of unknown primary sites are allowed if the clinical history and the site are highly suggestive of a skin cancer primary
• Tumor site must be amenable for surgical resection and accessible for pre-treatment biopsy
• Tumor site must be measurable by caliper measurements or by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 imaging - lesions must be ≥1 cm
• Eastern Cooperative Oncology Group (ECOG) ≤2 and be medically able to undergo surgical resection
• Laboratory Requirements: Hemoglobin ≥ 8 g/dl, Platelet count ≥ 50,000/dl, Serum Creatinine ≤ 1.5 mg/dL OR Glomular Filtration Rate (GFR) ≥ 40, Serum aspartate aminotransferase (AST) and alanine transaminase (ALT) \< 2.5x ULN; Total Bilirubin \< 1.5x ULN (for patients with documented history of Gilbert's syndrome, total bilirubin level should be \< 3.0 X ULN)
• Ability to understand and willingness to sign a written informed consent document
• Patients with child bearing potential must be willing to use barrier protection to prevent pregnancy while on study therapy and up to 30 days after the last dose of pramlintide
• Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• Patients must be willing to comply with the protocol for the duration of the treatment including daily sub-cutaneous (SQ) injections, biopsies, scheduled visits and examinations, radiologic studies, and surgical resection

You may not qualify if:

• Type I diabetes: Type II diabetics (DM2) on insulin are allowed, however, for those DM2 patients that are on short acting insulin, the insulin dose should be reduced 50% and need to have regular glucose monitoring (see section 6.2.1). Type II diabetics not on insulin will not be eligible.
• Patients with known gastroparesis
• Patients with known allergic reactions to pramlintide or its ingredients
• Pregnant women and/or nursing patients will be excluded from this study because of unknown risks to fetus or nursing infants
• Any serious or uncontrolled medical disorder that could interfere with the current study as deemed by the investigating physician
• Participation in any other clinical study using an investigational agent within 21 days of starting treatment on this protocol
• No prior chemotherapy, radiation, or other tumor directed therapy within 21 days prior of starting treatment on this protocol

Sponsors & Collaborators

• H. Lee Moffitt Cancer Center and Research Institute: lead

Study Sites (1)

Moffitt Cancer Center

Tampa, Florida, 33612, United States

Location

MeSH Terms

Interventions

pramlintide

Study Officials

• Nikhil Khushalani, MD

  Moffitt Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 30, 2020
• First Posted: February 5, 2020
• Study Start: January 30, 2020
• Primary Completion: June 26, 2023
• Study Completion: June 26, 2023
• Last Updated: June 28, 2023

Record last verified: 2023-06

Locations

US (1)